Strategic Partnerships Zumutor has formed a clinical collaboration with Coherus Oncology to conduct a Phase 1 trial of ZM008 in combination with a next-generation PD-1 inhibitor, indicating a strong interest in partnered development and in-licensing opportunities for combination therapies.

Financing momentum With a Series B (including a $7.3M raise) led by Accel, Bharat Innovation Fund and new investors, Zumutor demonstrates active capital raising and growth trajectory, suggesting readiness for co-development deals, milestone-driven partnerships, or out-licensing discussions.

Clinical readiness Lead asset ZM008 is advancing toward IND filing and early-phase trials, signaling a near-term opportunity to engage in discussions around investigator-sponsored trials, strategic alliances for trial execution, and potential asset co-development.

Global R&D reach R&D conducted in ISO-certified labs in Bangalore alongside headquarters in Cambridge, MA, presenting a dual-geography capability that can appeal to global CROs, manufacturing partners, and cross-border collaboration opportunities.

Immuno-oncology focus ZM008 targets NK cell activation and checkpoint pathways, creating potential sales angles with companies pursuing NK cell therapies, combination regimens, and biomarker-driven programs across solid tumors.